🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

Recruitingn/aAges 18 Years - anyAllRuijin Hospital
NCT06755775 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Pathologic diagnosis of DLBCL 2. Patient's general condition is good and survival is expected to be greater than six months 3. Signed and dated informed consent form Exclusion Criteria: 1. Combined with other malignant tumors 2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study 3. Pregnant women and women at risk of pregnancy, breastfeeding women 4. poor compliant
💊

What it tests

  • Not listed
📍

Where

1 site
Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy